thymopentin
load
polybutylcyanoacryl
pbca
nanoparticl
np
order
enhanc
oral
bioavail
prepar
nanoprecipit
method
dialyz
membran
method
employ
examin
vitro
releas
pb
sampl
releas
medium
detect
hplc
cell
prolifer
test
hthymidin
conduct
verifi
bioactiv
vitro
pharmacodynam
studi
perform
preimmunoinhibit
rat
flow
cytomet
size
entrap
effici
ae
nm
ae
respect
vitro
releas
data
show
less
releas
lyophil
releas
colloid
h
prolifer
test
show
similar
effect
vivo
data
show
oral
similar
function
intraven
oral
bioavail
could
enhanc
pbca
nanoparticl
properti
sustainedreleas
efficaci
chang
formul
oral
deliveri
peptid
protein
drug
becom
import
research
area
due
larg
number
recombin
protein
investig
therapeut
applic
superior
conveni
administr
patient
howev
biolog
enzymat
barrier
vivo
mainli
consist
gastric
acid
variou
enzym
present
scientist
great
challeng
develop
suitabl
prepar
oral
deliveri
peptid
protein
thymopentin
synthet
pentapeptid
correspond
activ
site
amino
acidhuman
hormon
thymopoietin
biolog
activ
thymopoietin
influenc
immun
system
promot
differenti
thymocyt
affect
function
matur
tcell
use
immunomodul
treatment
rheumatoid
arthriti
acquir
immunodefici
syndrom
aid
sever
acut
respiratori
syndrom
sar
cutan
tcell
lymphomacanc
immunodefici
primari
immunodefici
howev
halflif
clinic
use
via
intramuscular
administr
often
induc
inconveni
patient
sens
develop
oral
deliveri
system
great
scientif
practic
signific
nanoparticl
kind
immunogen
free
stabl
less
toxic
drug
deliveri
system
easi
prepar
lyophil
evid
reveal
nanoparticl
nm
may
absorb
intestin
way
either
paracellular
uptak
endocytosi
biodegrad
polym
wide
use
prepar
microparticul
drug
deliveri
system
polylact
acid
pla
poli
lactidecoglycolid
acid
plga
chitosan
etc
fragil
drug
encapsul
polymer
nanoparticl
thu
go
gi
tract
polybutylcyanoacryl
pbca
fine
biodegrad
polym
use
surgeri
glue
clinic
addit
former
experi
done
lab
show
method
produc
pbca
nanoparticl
much
easier
other
paper
pbca
select
carrier
materi
account
serial
screen
test
lab
base
drug
entrap
effici
ee
compar
pla
plga
nanoparticl
accord
literatur
difficult
water
insolubl
drug
encapsul
polym
compar
water
solubl
one
howev
highli
hydrophil
drug
present
anoth
challeng
studi
although
variou
method
prepar
polymer
nanoparticl
nanoprecipit
method
use
prepar
studi
effect
dose
mgday
respect
instruct
inject
use
clinic
therefor
reason
deliv
oral
dosag
form
long
amount
load
nanoparticl
suitabl
mous
antirat
cd
rpe
mous
antirat
cd
fitc
mous
antirat
cd
alpha
antibodi
obtain
serotec
ltd
oxford
uk
wistar
rat
bal
bc
mice
provid
westchina
experiment
anim
center
sichuan
univers
optim
nanoprecipit
method
use
prepar
nanoparticl
select
test
differ
prepar
condit
mg
care
weigh
dissolv
ml
pluron
solut
ph
solut
adjust
mol
l
hcl
fifti
microlit
pbca
drop
water
phase
slow
inject
stir
stir
min
ph
valu
solut
adjust
moll
naoh
kept
stir
anoth
h
colloid
freezedri
savant
instrument
inc
ny
store
use
size
nanoparticl
determin
masters
malvern
uk
triplic
morpholog
nanoparticl
observ
neg
stain
transmiss
electron
microscop
tem
hitachi
minatoku
japan
nanoparticl
colloid
drop
grid
dy
phosphotungst
acid
pta
pictur
shown
figur
obtain
nanoparticl
colloid
dilut
distil
water
ml
volumetr
flask
percentag
drug
incorpor
nanoparticl
determin
centrifug
hitachi
japan
drugload
nanoparticl
rpm
h
supernat
separ
free
drug
supernat
determin
hplc
shimadzu
kyoto
japan
nm
rp
c
column
mm
mm
mm
vydac
usa
mobil
phase
consist
pb
moll
ph
meoh
temperatur
flow
rate
mlmin
inject
volum
ml
ee
calcul
differ
amount
drug
entrap
total
amount
drug
releas
pbcanp
examin
follow
one
microlit
colloid
solut
lyophil
nanoparticl
solut
solut
contain
amount
mgml
put
dialysi
membran
tube
twenti
microlit
ph
phosphat
buffer
solut
use
medium
releas
test
tube
place
water
bath
maintain
shook
speed
rpm
given
time
interv
ml
releas
medium
withdrawn
ml
fresh
pb
ad
media
amount
solut
measur
hplc
analysi
cumul
releas
rate
nanoparticl
calcul
releas
curv
shown
figur
releas
data
fit
differ
pharmacokinet
releas
model
statistica
fig
vitro
efficaci
evalu
studi
use
cell
prolifer
assay
thymocyt
spleen
cell
collect
mice
suspend
rpmi
concentr
cellml
respect
mlwell
ad
plate
without
ml
concanavalin
con
mgml
triplic
rpmi
contain
bsa
media
ad
well
till
ml
well
ml
cell
suspens
ad
well
mix
kept
co
h
htdr
mci
ad
well
h
end
cultur
free
htdr
wash
distil
water
time
sampl
collect
onto
glass
microfib
filter
detect
liquid
scintil
counter
system
result
shown
figur
twentyeight
femal
wistar
rat
weigh
g
divid
seven
group
randomli
treat
cyclophosphamid
ctx
intraperiton
ip
day
continu
immun
inhibit
model
develop
accord
report
administr
done
follow
tabl
per
day
day
total
blood
sampl
ml
rat
collect
tube
precov
heparin
day
detect
flow
cytometri
analysi
epic
eliteesp
coulter
fullerton
ca
fig
one
hundr
microlit
blood
sampl
ad
ml
correspond
monoantibodi
vortex
stand
min
rt
ml
cell
lysi
buffer
ad
mixtur
stood
anoth
min
last
ml
pb
moll
ph
ad
vortex
stood
min
fc
analysi
chart
obtain
shown
figur
ratio
cd
cd
group
calcul
accordingli
calcul
paramet
shown
format
mean
valu
ae
standard
deviat
sd
comparison
experiment
group
correspond
control
student
ttest
employ
valu
p
set
signific
limit
calcul
p
exist
signific
differ
characterist
pbca
nanoparticl
lyophil
powder
clean
white
easi
resuspend
water
homogen
tem
nanoparticl
shown
figur
nanoparticl
observ
spheric
ellipsoid
shape
smooth
surfac
tem
colloid
lyophil
powder
month
rt
shown
figur
c
respect
result
demonstr
structur
nanoparticl
powder
stabl
nanoparticl
colloid
size
ae
nm
pluron
would
increas
size
nanoparticl
percentag
moreov
ph
valu
anoth
factor
influenc
nanoparticl
size
ph
valu
higher
particl
size
would
increas
significantli
ee
ae
data
show
ph
help
higher
ee
begin
nanoparticl
format
increas
increas
encapsul
effici
also
increas
particl
size
addit
increas
ratio
polymerdrug
would
increas
ee
releas
profil
colloid
powder
uncoat
shown
figur
releas
pattern
note
typic
biphas
burst
effect
drop
releas
curv
lyophil
nanoparticl
group
show
releas
amount
less
degrad
h
could
releas
lyophil
powder
least
h
differ
fit
model
result
shown
tabl
critic
valu
coeffici
r
paramet
chosen
colloid
releas
curv
fit
higuchi
weibul
biexpotenti
equat
p
releas
curv
lyophil
powder
fit
equat
list
tabl
respect
p
releas
curv
colloid
h
fit
well
follow
equat
paramet
set
r
data
show
releas
curv
could
describ
differ
equat
sum
calcul
select
best
equat
accord
follow
formula
smaller
sum
better
equat
fit
q
observ
valu
q
valu
calcul
accord
differ
equat
valu
list
tabl
comparison
observ
calcul
valu
vitro
releas
data
differ
prepar
shown
figur
indic
equat
could
mimic
releas
curv
vitro
well
weibul
equat
biexponenti
equat
vitro
cell
prolifer
assay
report
show
con
function
induc
cell
activ
hthymidin
incorpor
prolifer
assay
method
use
wide
evalu
cell
prolifer
vitro
con
abil
increas
cell
divis
figur
show
cell
group
without
con
limit
popul
cell
amount
group
treat
con
togeth
signific
increas
blank
pbcanp
function
stimul
prolifer
spleen
cell
decreas
effect
con
induc
prolifer
spleen
cell
vitro
could
collabor
con
increas
prolifer
free
vivo
efficaci
evalu
concentr
blood
determin
extrem
short
halflif
immunomodul
would
improv
inhibit
immun
system
cd
factor
figur
comparison
chart
differ
rat
group
n
valu
obtain
flow
cytometri
system
detect
signal
correspond
label
antibodi
suitabl
illustr
efficaci
administr
differ
form
prepar
cd
cd
chosen
indic
immun
improv
valu
cd
cd
rat
blood
decreas
treat
ctx
compar
treatment
group
ig
group
show
effect
increas
decreas
valu
cd
cd
blood
group
show
dosagedepend
effect
increas
cd
cd
like
effect
result
iv
group
fig
result
indic
administr
oral
deliv
rat
blood
success
protect
encapsul
pbca
nanoparticl
effect
oral
administr
promis
oral
deliveri
short
halflif
drug
student
ttest
perform
data
group
c
group
df
valu
cd
cd
control
group
signific
differ
salin
group
signific
differ
group
c
group
df
p
effectdosag
pharmaceut
effect
also
calcul
list
tabl
pharmacodynam
effect
group
highest
compar
ig
group
seem
like
drug
dosag
rat
might
give
best
result
depend
adjust
immun
system
unclear
mechan
studi
high
entrap
effici
prepar
optim
nanoprecipit
method
show
properti
sustain
releas
pb
maintain
biolog
efficaci
show
posit
cooper
con
prolifer
test
lymphocyt
transmiss
oral
pharmacodynam
studi
conduct
immunosuppress
rat
flow
cytometri
result
show
signific
improv
oral
absorpt
regular
uncoat
solut
mechan
work
immun
system
clear
yet
suitabl
dosag
treatment
test
come
conclus
studi
feasibl
promis
oral
deliveri
system
use
pbca
carrier
establish
enhanc
oral
absorpt
bioavail
peptid
protein
drug
acknowledg
financi
support
nation
natur
scienc
foundat
china
project
w
grate
prof
zhang
prof
jiang
instruct
phd
ae
g
control
dosag
adjust
effect
factor
differ
group
e
f
c
signific
p
dc
p
ec
p
fc
control
mean
rat
treat
noth
rat
immun
inhibit
degre
studi
also
thank
due
yu
nie
yunzhu
lin
provid
assist
research
